The Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market is anticipated to grow significantly at a CAGR of 3.5% over the forecast period (2020-2026). China, India, Japan, ASEAN, South Korea, and the Rest of Asia-Pacific are the major countries contributing to the growth of the Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors industry over the forecast period. The high prevalence of diabetes among the people in the region further supports the market growth. As per the International Diabetes Federation, over 250 million people in the region suffer from diabetes. Among these major economies of the region, China, India, and Japan are the most affected countries. China has the highest prevalence of diabetes in 2019 with around 116 million, India has the second-highest prevalence of diabetes followed by Japan, which significantly contributes to market growth.
A full report of Asia-Pacific Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market is available at: https://www.omrglobal.com/industry-reports/asia-pacific-dipeptidyl-peptidase-4-inhibitors-market
Some major factors that lead to diabetes in the region are the sedentary lifestyles of the people, the consumption of junk food which leads to obesity, and the rising geriatric population. Hence, such aforementioned factors lead to diabetes in the people which in turn creates a wide scope for the growth of the Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market. Some of the drugs available and approved in the region include Gemigliptin approved in Korea by LG Life Sciences; Anagliptin approved in Japan by Sanwa Kagaku Kenkyusho Co., Ltd., and Kowa Company, Ltd; Trelagliptin, Teneligliptin approved in Japan; and Evogliptin approved for use in South Korea. Hence, such factors are considered to be as growth aspects for the market in the Asia-Pacific region.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-dipeptidyl-peptidase-4-inhibitors-market
Market Coverage
- Market number available for – 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type
- Regions Covered- Asia-Pacific
- Competitive Landscape- Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily & Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, and Takeda Pharmaceutical Co. among others
Key questions addressed by the report
- What is the market growth rate?
- Which segment dominates the market in base year?
- Which segment will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Asia-Pacific Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Segmentation
By Type
- Sitagliptin
- Vildagliptin
- Saxagliptin
- Linagliptin
- Gemigliptin
- Anagliptin
- Teneligliptin
- Others
This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.
